High-Risk CSCC Trial Validates Cemiplimab’s Potential
Cemiplimab demonstrated a 68% reduction in recurrence risk for high-risk CSCC in the phase 3 C-POST trial, according to Regeneron’s latest findings.
Related Articles
Unveiling the Daily Struggles of Chronic Spontaneous Urticaria: Patient Perspectives and Diagnostic Challenges
Sponsored by Novartis Pharmaceuticals Corporation Sponsored by Novartis, this video series provides perspective on best practices for the assessment, diagnosis, and treatment of chronic spontaneous…
QRX003 Shows Promise in Pediatric Patients with Netherton Syndrome, Quoin Announces
Disease severity improved from severe to mild after just 6 weeks of twice daily dosage.
Spesolimab Response in a Patient With Steroid-Resistant Sweet Syndrome
This case report describes a patient with Sweet syndrome whose condition improved with spesolimab after failure of high-dose corticosteroids.
Study Highlights Patient-Driven Risk Tolerance for Ritlecitinib in Severe Alopecia Areata
A new analysis highlights the importance of patient preferences in optimizing treatment strategies for severe alopecia areata.
The Intersection of Ethics, Aesthetics, and Patient Expectations in Dermatology
Balancing ethics, aesthetics, and patient expectations is crucial in dermatology to ensure safe, responsible, and ethical care.
Rare Overlap of 2 Autoinflammatory Keratinization Diseases Observed in Single Lesion
A case study explores a rare overlap of hidradenitis suppurativa and porokeratosis, highlighting unique histopathology and complications.
Pili Annulati
This case report describes a teenage girl with glistening hair and was found to have alternating dark and light bands within the hair shafts on…
Smooth, Firm, Skin-Colored Papules on the Nasal Dorsum
A healthy 19-year-old man with Fitzpatrick skin type V presented with a 2-year history of smooth, firm, skin-colored papules on the nasal dorsum and bilateral…
A New Year and New Beginnings
The Practical Dermatology Podcast returns with the latest news to start 2025 and a conversation between Chief Medical Editor Neal Bhatia, MD, FAAD, and ne…
The Unprecedented Phase 1 Results of ET-02 for the Treatment of Androgenic Alopecia
Jon Edelson, MD, CEO of Eirion, confirms that topical ET-02 is a completely new approach to treating this type of hair loss.